Literature DB >> 21826023

Aldosterone as a modulator of immunity: implications in the organ damage.

Andrés A Herrada1, Carmen Campino, Cristián A Amador, Luis F Michea, Carlos E Fardella, Alexis M Kalergis.   

Abstract

High plasmatic levels of aldosterone cause hypertension and contribute to progressive organ damage to the heart, vasculature, and kidneys. Recent studies have demonstrated a role for the immune system in these pathological processes. Aldosterone promotes an inflammatory state characterized by vascular infiltration of immune cells, reactive oxidative stress, and proinflammatory cytokine production. Further, cells of the adaptive immune system, such as T cells, seem to participate in the genesis of mineralocorticoid hormone-induced hypertension. In addition, the observation that aldosterone can promote CD4⁺ T-cell activation and Th17 polarization suggests that this hormone could contribute to the onset of autoimmunity. Here we discuss recent evidence supporting a significant involvement of the immune system, especially adaptive immunity, in the genesis of hypertension and organ damage induced by primary aldosteronism. In addition, possible new therapeutic approaches consisting of immunomodulator drugs to control exacerbated immune responses triggered by elevated aldosterone concentrations will be described.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826023     DOI: 10.1097/HJH.0b013e32834a4c75

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  28 in total

1.  Relationships of hardiness to physical and mental health status in military men: a test of mediated effects.

Authors:  Marcus K Taylor; Ricardo Pietrobon; John Taverniers; Matthew R Leon; Benedict J Fern
Journal:  J Behav Med       Date:  2011-11-23

2.  Hypertension: is it time to replace drugs with nutrition and nutraceuticals?

Authors:  Walter Alexander
Journal:  P T       Date:  2014-04

Review 3.  The role of nutrition and nutraceutical supplements in the treatment of hypertension.

Authors:  Mark Houston
Journal:  World J Cardiol       Date:  2014-02-26

4.  Adrenal histologic findings show no difference in clinical presentation and outcome in primary hyperaldosteronism.

Authors:  Allison B Weisbrod; Richard C Webb; Aarti Mathur; Stephanie Barak; Smita Baid Abraham; Naris Nilubol; Martha Quezado; Constantine A Stratakis; Electron Kebebew
Journal:  Ann Surg Oncol       Date:  2012-10-23       Impact factor: 5.344

Review 5.  Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price
Journal:  Endocrine       Date:  2018-08-02       Impact factor: 3.633

Review 6.  The ubiquitous mineralocorticoid receptor: clinical implications.

Authors:  Urseline A Hawkins; Elise P Gomez-Sanchez; Clara M Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

7.  Chronic aldosterone administration causes Nox2-mediated increases in reactive oxygen species production and endothelial dysfunction in the cerebral circulation.

Authors:  Sophocles Chrissobolis; Grant R Drummond; Frank M Faraci; Christopher G Sobey
Journal:  J Hypertens       Date:  2014-09       Impact factor: 4.844

Review 8.  The Potential Role of Aldosterone-Producing Cell Clusters in Adrenal Disease.

Authors:  Jung Soo Lim; William E Rainey
Journal:  Horm Metab Res       Date:  2020-03-30       Impact factor: 2.936

Review 9.  Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

Authors:  Hermann Haller; Anna Bertram; Klaus Stahl; Jan Menne
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 10.  Autoimmunity in the pathogenesis of hypertension.

Authors:  Bernardo Rodríguez-Iturbe; Héctor Pons; Yasmir Quiroz; Miguel A Lanaspa; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2013-11-19       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.